Hims & Hers Health, Inc. insider trading
Every open-market purchase and sale by Hims & Hers Health, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Hims & Hers Health, Inc.’s insiders pay?
From July 22, 2021 to May 26, 2026, 17 insiders reported 8 open-market purchases and 28 sales not made under a pre-set plan in Hims & Hers Health, Inc. Twelve months after each purchase was reported, the shares were +78.3% against the S&P 500 on average (median +48.7%), over 4 purchases with a full year of prices; 75% beat the index. After sales, the shares moved +57.3% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on August 31, 2021 into $21,230 by November 2, 2026, +15.7% a year. It held shares 62% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $12,467 (+4.4% a year), and held throughout $17,969 (+12.1%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Carroll Patrick Harrison | Chief Medical Officer | 0 | — | — | 8 | +73.4% (7) | August 8, 2025 |
| Wells David B | Director | 2 | −8.1% (1) | 0% | 3 | +72.9% (3) | May 26, 2026 |
| Dudum Andrew | Chief Executive Officer | 1 | +26.5% (1) | 100% | 2 | −42.7% (2) | August 11, 2025 |
| Maltz Jules A. | 10% owner | 2 | — | — | 1 | +15.7% (1) | March 6, 2023 |
| O'keefe Lynne Chou | Director | 0 | — | — | 3 | +103.7% (1) | June 22, 2022 |
| Pendarvis Christiane | Director | 0 | — | — | 3 | +156.1% (3) | March 6, 2025 |
| Abraham Jack | 10% owner | 0 | — | — | 1 | +19.9% (1) | December 16, 2021 |
| Baird Melissa | Chief Operating Officer | 0 | — | — | 1 | −22.9% (1) | July 22, 2021 |
| Bard Alex | Director | 0 | — | — | 1 | +11.1% (1) | March 3, 2023 |
| Becklund Irene | PAO | 0 | — | — | 1 | — | March 2, 2022 |
| Boughton Soleil | Chief Legal Officer | 0 | — | — | 1 | −22.9% (1) | July 22, 2021 |
| Chi Michael | Chief Marketing Officer | 0 | — | — | 1 | +120.7% (1) | March 1, 2024 |
| Lee Spencer | Chief Financial Officer | 0 | — | — | 1 | −22.9% (1) | July 22, 2021 |
| Manuel Anja | Director | 1 | +71.0% (1) | 100% | 0 | — | November 14, 2024 |
| Okupe Oluyemi | Chief Financial Officer | 1 | — | — | 0 | — | May 23, 2022 |
| Payne Christopher D | Director | 1 | +223.8% (1) | 100% | 0 | — | May 22, 2024 |
| Perez Garcia Andrea G | Director | 0 | — | — | 1 | — | December 10, 2025 |
When several insiders traded Hims & Hers Health, Inc.
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Hims & Hers Health, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After 4 selling crowds, −14.3%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| March 28, 2024 | 3 selling | +26.1% | +4.9% | +92.1% |
| March 31, 2023 | 4 selling | −17.0% | −40.1% | +27.6% |
| March 31, 2022 | 3 selling | +5.1% | +24.9% | +100.9% |
| July 30, 2021 | 5 selling | −4.9% | −46.8% | −16.2% |